1190979-31-7

Basic information

• Product Name: 5-fluoro-2-(4-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenoxy)piperidin-1-yl)pyrimidine
• Synonyms: 5-fluoro-2-(4-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenoxy)piperidin-1-yl)pyrimidine
• CAS NO: 1190979-31-7
• Molecular Weight: 449.549
• Mol File: 1190979-31-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-fluoro-2-(4-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenoxy)piperidin-1-yl)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-fluoro-2-(4-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenoxy)piperidin-1-yl)pyrimidine(1190979-31-7)
• EPA Substance Registry System: 5-fluoro-2-(4-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenoxy)piperidin-1-yl)pyrimidine(1190979-31-7)

Safety Data

• Hazardous Substances Data: 1190979-31-7(Hazardous Substances Data)

Upstream product

• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 1190979-26-0 N-tert-butyl 4-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenoxy)piperidine-1-carboxylate 
• 55276-43-2 4-methanesulfonylpiperazine 
• 207798-38-7 4-(4-formylphenoxy)piperidine-1-carboxylic acid t-butyl ester 
• 62802-42-0 2-chloro-5-fluoropyrimidine 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119; such as, but not limited to, diabetes, obesity and associated metabolic disorders. Formula (I) is a compound, in which A can have up to 2 ring -CH2- group substituted with -C(O)- and can be partially unsaturated with up to 2 double bonds; Wi and W2 are independently selected from CR10 and N; wherein R10 is selected from hydrogen and C1_6alkyl; Yi is selected from NRn, O and S; wherein Rn is selected from hydrogen and C1_ 6alkyl; Y2 and Y3 are independently selected from CH and N; Y4 is selected from CH2, OCH2 and NR15; wherein R15 is selected from hydrogen and C1_6alkyl; or the pharmaceutically acceptable salts thereof.